K2M Group Holdings Inc. (NASDAQ:KTWO) shot up 4.8% on Wednesday . The stock traded as high as $16.74 and last traded at $16.54, with a volume of 304,024 shares traded. The stock had previously closed at $15.78.

Several research analysts have recently issued reports on KTWO shares. Piper Jaffray Cos. reissued a “buy” rating on shares of K2M Group Holdings in a research note on Saturday, April 2nd. Needham & Company LLC reissued a “buy” rating and issued a $21.00 price target on shares of K2M Group Holdings in a research note on Tuesday, May 3rd. Northland Securities cut K2M Group Holdings from an “outperform” rating to a “market perform” rating in a research note on Tuesday, May 3rd. Zacks Investment Research cut K2M Group Holdings from a “hold” rating to a “sell” rating in a research note on Wednesday, May 4th. Finally, JMP Securities reissued a “buy” rating and issued a $22.00 price target on shares of K2M Group Holdings in a research note on Sunday, June 5th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $23.25.

The stock’s market capitalization is $671.64 million. The firm’s 50-day moving average is $13.94 and its 200 day moving average is $14.31.

K2M Group Holdings (NASDAQ:KTWO) last announced its quarterly earnings data on Monday, May 2nd. The medical device company reported ($0.25) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by $0.02. The firm earned $56.20 million during the quarter, compared to the consensus estimate of $56 million. During the same quarter in the previous year, the firm earned ($0.37) earnings per share. The company’s quarterly revenue was up 11.7% compared to the same quarter last year. Equities analysts forecast that K2M Group Holdings Inc. will post ($1.10) EPS for the current fiscal year.

In related news, CFO Gregory S. Cole sold 6,465 shares of the firm’s stock in a transaction that occurred on Saturday, May 21st. The stock was sold at an average price of $11.32, for a total transaction of $73,183.80. Following the completion of the transaction, the chief financial officer now owns 33,233 shares in the company, valued at approximately $376,197.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Carlos A. Ferrer bought 20,000 shares of the business’s stock in a transaction that occurred on Thursday, May 5th. The shares were bought at an average price of $11.32 per share, with a total value of $226,400.00. Following the transaction, the director now directly owns 59,382 shares in the company, valued at $672,204.24. The disclosure for this purchase can be found here.

Several institutional investors recently bought and sold shares of the company. Nationwide Fund Advisors increased its position in K2M Group Holdings by 3.8% in the fourth quarter. Nationwide Fund Advisors now owns 98,318 shares of the medical device company’s stock valued at $1,941,000 after buying an additional 3,597 shares during the period. New York State Common Retirement Fund increased its position in shares of K2M Group Holdings by 1.6% in the fourth quarter. New York State Common Retirement Fund now owns 141,690 shares of the medical device company’s stock valued at $2,797,000 after buying an additional 2,170 shares during the last quarter. Paradigm Capital Management Inc. NY increased its position in shares of K2M Group Holdings by 625.2% in the fourth quarter. Paradigm Capital Management Inc. NY now owns 169,700 shares of the medical device company’s stock valued at $3,350,000 after buying an additional 146,300 shares during the last quarter. Principal Financial Group Inc. increased its position in shares of K2M Group Holdings by 1.3% in the fourth quarter. Principal Financial Group Inc. now owns 398,277 shares of the medical device company’s stock valued at $7,862,000 after buying an additional 5,127 shares during the last quarter. Finally, Columbus Circle Investors increased its position in shares of K2M Group Holdings by 20.4% in the fourth quarter. Columbus Circle Investors now owns 510,062 shares of the medical device company’s stock valued at $10,069,000 after buying an additional 86,497 shares during the last quarter.

K2M Group Holdings, Inc is a medical device company focused on designing, developing and commercializing spine technologies and techniques. The Company’s spine products are used by spine surgeons to treat spinal pathologies, such as deformity (primarily scoliosis), trauma and tumor. The Company is engaged in designing, development and commercialization of products for patients suffering from degenerative spinal conditions.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.